Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.43 |
| ▸ | NLN | Q9BYT8 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18804713 | 1.00 | CYP3A4 (0.43) | CYP3A4SLC7A5NLN | |
| SCHEMBL18878681 | 0.80 | CYP3A4 (0.51) | CYP3A4SLC7A5NLN | |
| SCHEMBL18804657 | 0.80 | CYP3A4 (0.44) | CYP3A4SLC7A5NLN | |
| SCHEMBL18804654 | 0.80 | CYP3A4 (0.44) | CYP3A4SLC7A5NLN | |
| SCHEMBL18878676 | 0.78 | CYP3A4 (0.56) | CYP3A4SLC7A5NLN | |
| SCHEMBL28333429 | 0.74 | CYP3A4 (0.57) | CYP3A4SLC7A5NLN | |
| SCHEMBL18804667 | 0.74 | CYP3A4 (0.51) | CYP3A4SLC7A5NLN | |
| SCHEMBL18804665 | 0.74 | HRH3 (0.46) | CYP3A4SLC7A5 | |
| SCHEMBL18804666 | 0.74 | HRH3 (0.46) | CYP3A4SLC7A5 | |
| SCHEMBL18804668 | 0.74 | HRH3 (0.46) | CYP3A4SLC7A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9795566-B2 | Imidazole compound and liposome containing same | FUJIFILM CORPORATION (JP) | 2017-10-24 | — | — | US | disclosed |
| US-20170119667-A1 | IMIDAZOLE COMPOUND AND LIPOSOME CONTAINING SAME | FUJIFILM CORPORATION (JP) | 2017-05-04 | — | — | US | disclosed |
| US-20150266851-A1 | Multifunctional Radical Quenchers For The Treatment Of Mitochondrial Dysfunction | ARIZONA BOARD OF REGENTS, A BODY CORPORATE OF THE STATE OF ARIZONA ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2015-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266851-A1 | Multifunctional Radical Quenchers For The Treatment Of Mitochondrial Dysfunction | GSR, SQOR, TXNRD2 | CYP3A4 1068/4885SLC7A5 2351/4885NLN 114/4885 |
| US-20170119667-A1 | IMIDAZOLE COMPOUND AND LIPOSOME CONTAINING SAME | NPC1L1, LETM1, STOML2 | CYP3A4 2661/4885SLC7A5 76/4885NLN 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.